Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @OrentasR
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @OrentasR
-
Prikvačeni tweet
A man I loved always- to know him even a little was to be deeply influenced by him
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
PIs who have 2 or more RO1s taking advice from administratorshttps://twitter.com/bja_samuel/status/1220337225344475137 …
2:02Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
R Orentas proslijedio/la je Tweet
Don’t know if any of you have tried to report these-it’s a lot of data that isn’t routinely collected in investigator initiated studies and is very time consuming to gather and enter if you’re an investigator. Some NIH bureaucrats came up with this
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
Mid-career, early career with evidence of productivity, serious package available for researcher interested in
#glioblastoma#DIPG -new space, in vivo models at any scale, clinical appt if desired (MD, DVM), Ben Towne Center for Childhood Cancer Research. SCRI Seattle.Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
R Orentas proslijedio/la je Tweet
After a
#Measles Scare, Seattle Cracks Down on Vaccine Compliance#VaccinesWorkhttps://nyti.ms/2FJpYmVHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
R Orentas proslijedio/la je Tweet
Barstool Sports has a new Fight With Oskar shirts, where 100% of the net proceeds will go towards the fight against Ewing’s Sarcoma. Buy NOW!https://store.barstoolsports.com/products/fight-with-o-tee?variant=31538689081441 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
R Orentas proslijedio/la je Tweet
"Why having a monopoly on the product combined with a captive market for it does not violate antitrust law is unclear to us."https://dooz.us/2Qg8apv
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
R Orentas proslijedio/la je Tweet
Thanks Hopes & Smiles for Children for supporting cancer
#immunotherapy research! Yesterday Dr. Vandana Kalia, Dr.@OrentasR & Dr. Surojit Sarkar gratefully accepted a gift that will bring hope to kids facing#childhoodcancer & smiles to our entire@seattlechildren 's community.pic.twitter.com/2nue8lUU5U
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
R Orentas proslijedio/la je Tweet
The openxlsx package works like a charm
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
R Orentas proslijedio/la je Tweet
2019 in Review - Our Division recently announced that CAR-T cell production
@FredNatLab will start soon in support of a multi-center#ClinicalTrial in pediatric acute myeloid leukemia. Read about this exciting@theNCI project here: https://buff.ly/2sy5vxO#NCIHighlights2019pic.twitter.com/xyassmmHvk
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
R Orentas proslijedio/la je Tweet
Remy and Sadie it was amazing spending time with you and hope you have a Merry Christmas!pic.twitter.com/r9wbybregY
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
R Orentas proslijedio/la je Tweet
Nice work
@straathof_karin. Not everyday you get a Science paper.https://science.sciencemag.org/content/366/6470/1247.full …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Phil Greenberg
@fredhutch delivering the E Donall Thomas lecture at#ASH19 showing us the characteristics of T cells that mediate prevention of AML relapse. An amazing 40 yr#immunotherapy tour de force - thank you Phil you inspire us allpic.twitter.com/ks6Sl4pWiY
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
R Orentas proslijedio/la je Tweet
ASH power trio! 3 outstanding women in hematology/leukemia/cell therapy. L to R: Rebecca Gardner, Sarah Tasian, and Lia Gore.
#ASH19#CARTcell@PedCancerCare@seattlechildren@ChildrensColopic.twitter.com/tMXpKE3GF4
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Dr Ferrari reports on the 9 pts treated with LV for
#betathal at#ASH19 -notable for chemo regimen to prep and direct injection of CD34 transduced cells into marrow to prevent organ filtering- we are 3 years out- 4 are transfusion independent: correlates trsdctn efficiencypic.twitter.com/q3Iy1IM6MG
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
The great Feng Zhang developing the next generation of specific genome editors
#ASH19 this is why go to ASH@broadinstitutepic.twitter.com/SxdA0qQ3r8
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
You want data? Dr Xian Zhang has data in over 250 patients who got CD19 CART products. No question that in this generation of products HSCT makes a big impact. Impressive data set and presentation!
#ASH19#immunotherapy#CARTcellpic.twitter.com/9n460xrAaS
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Dr E Stadtmauer presented the amazing success of making an NY-ESO1 TCR via LV and CRISPERed endogenous TCR &PD1-This is why we come to
#ASH19 ! Chromosomal translocations were seen in the first set of 3 patients -no doubt we need safety switches@parkerici@TmunityTx@PennCancerHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
How much does CAR-T cost in an academic IND setting : here is the
@caseccc CWRU calculated cost. No excuse to hold back innovation for our patients!#manufacturelocal#ASH2019@miltenyibiotec excellent talk by Jane Reesepic.twitter.com/9saFGeSFbZ
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.